Skip to main content
. 2020 Mar 5;10:296. doi: 10.3389/fonc.2020.00296

Figure 4.

Figure 4

c-MYC expression contributes to AZD1775 resistance. (A–C) AZD1775-naive and -resistant Molm13 (A), Jurkat (B), and REH (C) cells were treated with panobinostat (10 nM), vorinostat (1 μM), and/or AZD1775 (0.5 or 1 μM) for 24 h after which protein lysates were subjected to western blotting with antibodies specific to c-MYC and actin. (D–F) AZD1775-naïve Molm13 (D), Jurkat (E) and REH (F) cells were transfected with MIG or MIG-c-MYC plasmids and cultured with 200 nM AZD1775 or 0.02% DMSO (UT). The percentage of GFP+ cells was measured and the cells were re-plated with fresh media and drug every 72 h. (G–I) AZD1775-naive and -resistant Molm13 (G), Jurkat (H), and REH (I) cells were treated with the indicated concentration of JQ1 and/or 50–2,000 nM AZD1775 for 72 h. Viable cell counts normalized to cells receiving no AZD1775 treatment (NT) are shown. Results are displayed as mean ± SEM from three independent experiments. *P < 0.05, ** P < 0.01, ***P < 0.001, ****P < 0.0001.